NEJM paper calls for more regulation of mobile health apps

With the rise of high-risk, high-reward mobile health devices and apps, the FDA needs to add funding and tools towards regulation of the rapidly expanding industry, experts wrote in the New England Journal of Medicine. While most mHealth devices have relatively low risk, health monitoring devices are within FDA jurisdiction and authority. Some believe that FDA regulation will stifle innovative mHealth production, but experts argue that removing FDA oversight will only allow for ineffective and risky devices to infiltrate an unchecked market. Abstract

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.